Akeso, Inc. (HKG:9926)
86.25
-0.70 (-0.81%)
May 30, 2025, 11:45 AM HKT
Akeso Revenue
In the year 2024, Akeso had annual revenue of 2.12B CNY, down -53.08%. Akeso had revenue of 1.10B in the half year ending December 31, 2024, with 62.96% growth.
Revenue
2.12B CNY
Revenue Growth
-53.08%
P/S Ratio
34.53
Revenue / Employee
699.82K CNY
Employees
3,035
Market Cap
78.04B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 32.53B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Innovent Biologics | 10.03B |
Sino Biopharmaceutical | 30.72B |
CSPC Pharmaceutical Group | 30.87B |
Alibaba Health Information Technology | 32.81B |
Akeso News
- 4 weeks ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 4 weeks ago - China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug - South China Morning Post
- 4 weeks ago - What's Going On With Summit Therapeutics Stock On Friday? - Benzinga
- 5 weeks ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 5 weeks ago - Akeso (9926) Poised for Growth Despite Current Undervaluation - GuruFocus
- 5 weeks ago - Bullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks Remain - Seeking Alpha
- 6 weeks ago - Why This Chinese Biotech Could Be Pharma's DeepSeek - Benzinga
- 2 months ago - Akeso reports FY results - Seeking Alpha